Terms: = Sarcomas AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
31 results:
1. Pharmacological ezh2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract] [Full Text] [Related]
2. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
3. ezh2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
Lin ZS; Chung CC; Liu YC; Chang CH; Liu HC; Liang YY; Huang TL; Chen TM; Lee CH; Tang CH; Hung MC; Chen YH
Elife; 2023 Jan; 12():. PubMed ID: 36622753
[TBL] [Abstract] [Full Text] [Related]
4. Circular RNA_ANKIB1 accelerates chemo-resistance of osteosarcoma via binding microRNA-26b-5p and modulating enhancer of zeste homolog 2.
Tang J; Duan G; Wang Y; Wang B; Li W; Zhu Z
Bioengineered; 2022 Mar; 13(3):7351-7366. PubMed ID: 35264070
[TBL] [Abstract] [Full Text] [Related]
5. Epithelioid sarcoma: A clinicopathological study of 12 head and neck cases.
Shi CJ; Xu SM; Li CW; Tian Z; Wang LZ; Hu YH; Xia RH; Zhang ZY; Li J
Oral Dis; 2022 Sep; 28(6):1519-1527. PubMed ID: 33751732
[TBL] [Abstract] [Full Text] [Related]
6. The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.
Liu K; Ni JD; Li WZ; Pan BQ; Yang YT; Xia Q; Huang J
Mol Oncol; 2020 Oct; 14(10):2678-2695. PubMed ID: 32634265
[TBL] [Abstract] [Full Text] [Related]
7. Targeting ezh2 by microRNA-449a inhibits osteosarcoma cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-mesenchymal transition.
Lu DG; Tang QL; Wei JH; He FY; Lu L; Tang YJ
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1656-1665. PubMed ID: 32141531
[TBL] [Abstract] [Full Text] [Related]
8. [SMARCA4-deficient thoracic tumors: A new entity].
Decroix E; Leroy K; Wislez M; Fournel L; Alifano M; Damotte D; Mansuet-Lupo A
Bull Cancer; 2020 Jan; 107(1):41-47. PubMed ID: 31916995
[TBL] [Abstract] [Full Text] [Related]
9. Discovery of a first-in-class ezh2 selective degrader.
Ma A; Stratikopoulos E; Park KS; Wei J; Martin TC; Yang X; Schwarz M; Leshchenko V; Rialdi A; Dale B; Lagana A; Guccione E; Parekh S; Parsons R; Jin J
Nat Chem Biol; 2020 Feb; 16(2):214-222. PubMed ID: 31819273
[TBL] [Abstract] [Full Text] [Related]
10. SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature.
Stewart BD; Kaye F; Machuca T; Mehta HJ; Mohammed TL; Newsom KJ; Starostik P
Int J Surg Pathol; 2020 Feb; 28(1):102-108. PubMed ID: 31382829
[TBL] [Abstract] [Full Text] [Related]
11. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract] [Full Text] [Related]
12. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21.
Ren Z; Hu Y; Li G; Kang Y; Liu Y; Zhao H
Biomed Pharmacother; 2019 Sep; 117():109104. PubMed ID: 31228799
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA LSINCT5 acts as an oncogene via increasing ezh2-induced inhibition of APC expression in osteosarcoma.
Kong D; Li C; Yang Q; Wei B; Wang L; Peng C
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):193-197. PubMed ID: 30420287
[TBL] [Abstract] [Full Text] [Related]
14. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via ezh2.
Gu W; Zhang E; Song L; Tu L; Wang Z; Tian F; Aikenmu K; Chu G; Zhao J
Biomed Pharmacother; 2018 Oct; 106():890-895. PubMed ID: 30119259
[TBL] [Abstract] [Full Text] [Related]
15. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and ezh2.
Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
[TBL] [Abstract] [Full Text] [Related]
16. Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels.
Huang J; Deng G; Liu T; Chen W; Zhou Y
Biochem Biophys Res Commun; 2018 Jan; 495(4):2622-2629. PubMed ID: 29291409
[TBL] [Abstract] [Full Text] [Related]
17. TUG1 promotes osteosarcoma tumorigenesis by upregulating ezh2 expression via miR-144-3p.
Cao J; Han X; Qi X; Jin X; Li X
Int J Oncol; 2017 Oct; 51(4):1115-1123. PubMed ID: 28902349
[TBL] [Abstract] [Full Text] [Related]
18. Enhancer of zeste homologue 2 (ezh2) expression in synovial sarcomas as a promising indicator of prognosis.
Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
[TBL] [Abstract] [Full Text] [Related]
19. Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth.
Bao X; Ren T; Huang Y; Sun K; Wang S; Liu K; Zheng B; Guo W
Cell Death Dis; 2017 Feb; 8(2):e2605. PubMed ID: 28182000
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of ezh2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract] [Full Text] [Related]
[Next]
